Bharat Biotech

BBV154 is an intra-nasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine

Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria

Data from both phase-III human clinical trials have been submitted for approval to National Regulatory Authorities

The Drug Controller General of India (DCGI) gave its nod to conduct clinical trials for Bharat Biotech’s intranasal vaccine as…

Subjects were evaluated for safety, neutralising antibody responses against variants of concern, binding antibodies against spike…

Ocugen’s partner Bharat Biotech’s phase-II/III study of Covaxin (BBV152) in 526 children showed safety, efficacy, and superior…

The antibody response, clinical observations, viral load reduction and lung disease severity after virus challenge were observed…

The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a…

CEPI will fund the researchers to conduct activities including immunogen design, pre-clinical studies, manufacturing process…

The study is likely to be conducted at six sites, including AIIMS Delhi and Patna